Application of orange essential oil as an antistaphylococcal agent in a dressing model
© Muthaiyan et al.; licensee BioMed Central Ltd. 2012
Received: 5 November 2011
Accepted: 8 August 2012
Published: 16 August 2012
Staphylococcus aureus is the pathogen most often and prevalently involved in skin and soft tissue infections. In recent decades outbreaks of methicillin-resistant S. aureus (MRSA) have created major problems for skin therapy, and burn and wound care units. Topical antimicrobials are most important component of wound infection therapy. Alternative therapies are being sought for treatment of MRSA and one area of interest is the use of essential oils. With the increasing interest in the use and application of natural products, we screened the potential application of terpeneless cold pressed Valencia orange oil (CPV) for topical therapy against MRSA using an in vitro dressing model and skin keratinocyte cell culture model.
The inhibitory effect of CPV was determined by disc diffusion vapor assay for MRSA and vancomycin intermediate-resistant S. aureus (VISA) strains. Antistaphylococcal effect of CPV in an in vitro dressing model was tested on S. aureus inoculated tryptic soya agar plate. Bactericidal effect of CPV on MRSA and VISA infected keratinocyte cells was examined by enumeration of extra- and intra-cellular bacterial cells at different treatment time points. Cytotoxic effects on human skin cells was tested by adding CPV to the keratinocyte (HEK001) cells grown in serum free KSFM media, and observed by phase-contrast microscope.
CPV vapour effectively inhibited the MRSA and VISA strains in both disc diffusion vapour assay and in vitro dressing model. Compared to untreated control addition of 0.1% CPV to MRSA infected keratinocyte decreased the viable MRSA cells by 2 log CFU/mL in 1 h and in VISA strain 3 log CFU/mL reduction was observed in 1 h. After 3 h viable S. aureus cells were not detected in the 0.2% CPV treatment. Bactericidal concentration of CPV did not show any cytotoxic effect on the human skin keratinocyte cells in vitro.
At lower concentration addition of CPV to keratinocytes infected with MRSA and VISA rapidly killed the bacterial cells without causing any toxic effect to the keratinocytes. Therefore, the results of this study warrant further in vivo study to evaluate the potential of CPV as a topical antistaphylococcal agent.
KeywordsMRSA VISA S. aureus Antibiotic resistance Natural antimicrobials Orange essential oil
The highly adaptive S. aureus is the causative agent of a wide variety of human infections, ranging from superficial skin infections to deep abscesses and more serious life threatening infections. Since the 1990s, methicillin-resistant S. aureus (MRSA) has accounted for an increasing proportion of community associated infections in the U.S.[1, 2]. MRSA has become a primary cause of skin and soft tissue infections among persons without extensive exposure to healthcare settings. Data obtained from nationally representative ambulatory care surveys in the U.S. show that the infections associated with skin and soft-tissue increased from 8.6 million in 1997 to 14.2 million in 2005. Skin and soft tissue infections (SSTIs) involve microbial invasions of the primary host defence barriers epidermis and underlying soft tissues[4, 5]. Likewise, patients hospitalized with burn wounds are at increased risk of developing microbial colonization and infection caused by S. aureus. Previous studies revealed that S. aureus is the most frequently isolated bacterial species among the other pathogens from the burn wounds[6, 7].
Generally dressings and topical antimicrobial agents are routinely used to prevent skin and burn infections and also to keep the wound moist to promote healing. Although, a small number of antibiotics are used as prophylactics to prevent wound infection they are not routinely administered to burn patients due to the high cost and the risk of adverse side effects. Since, the constant use of antibiotics select the bacterial populations including S. aureus that are resistant to multiple antibiotics alternative therapies and new medical practices are very much needed[9–11]. One such approach is the search of biologically active pharmacophores from natural resources and traditional medicines[12–16]. Natural products have been investigated and utilized to alleviate disease since early human history. Before the “synthetic era”, 80% of all medicines were obtained from roots, barks, leaves, flowers, seeds and fruits.
Numerous studies have explored the promising novel antimicrobial candidates from plant derived essential oils (EOs). These EOs are particularly interesting since some oils have been used by native groups for curative purposes in the past[18, 19]. Many plants EOs have demonstrated for antimicrobial activity against variety of bacterial pathogens[20, 21]. One such a prominent example is tea tree oil obtained from the Australian tree Melaleuca alternifolia. Tea tree oil has been shown to be active against a wide range of microorganisms including S. aureus[20, 22]. In previous studies the antimicrobial activities of EOs have also been investigated and their actions against various pathogens, including clinical MRSA isolates, have been demonstrated[23–30].
Fisher et al. reported the effectiveness of citrus EOs and vapours of lemon and the citrus EO components citral, limonene, and linalool against a number of common foodborne pathogens Listeria monocytenes, S. aureus, Bacillus cereus, E. coli O157, and Campylobacter jejuni both in vitro and on food models. In our laboratory we have demonstrated the inhibition of Salmonella, Listeria[33, 34], Escherichia coli O157: H7, Campylobacter, and methicillin resistant S. aureus by citrus derived cold pressed Valencia orange oil, terpeneless Valencia orange oil, cold pressed orange terpenes, high purity orange terpenes, d-limonene, and terpenes from orange essence. In our previous study the inhibitory and cell wall lytic effect of 0.1% and 0.2% cold pressed terpeneless Valencia orange oil (CPV) against MRSA and VISA was demonstrated by disc diffusion and agar dilution methods and confirmed by genomic transcriptional profiling and electron microscopy. With the increasing interest in the use and application of natural antimicrobial agents for the therapy in the present study we evaluated the potential of CPV for topical therapy against MRSA by determining the antistaphylococcal effect of CPV in dressing model and S. aureus infected keratinocyte cell culture study.
Methicillin-susceptible S. aureus strain SH1000, methicillin-resistant strains COL, 13136 p-m+, and N315, and vancomycin intermediate-resistant strains 13136 p-m+ V20, and Mu50 were used in this study. Depending on the experimental condition described in the following sections bacterial strains were grown in either tryptic soya broth (TSB) or tryptic soya agar (TSA) media (Difco Laboratories, Inc. Detroit, MI) and incubated at 37°C for 18 h.
Orange essential oil
Commercially available terpeneless cold pressed Valencia orange oil was obtained from Firmenich Citrus Center, Safety Harbor, FL, USA. CPV is derived from mechanical extraction of the orange oil which is further concentrated under vacuum. The major components of CPV are Linalool 20.2%, Decanal 18%, Geranial 9.1%, α-Terpineol 5.8%, Valencene 5.2%, Neral 5%, Dodecanal 4.1%, Citronellal 3.9%, and Limonene 0.3%. The most predominant compounds are the alcohol linalool (20.2%) followed by decanal (18%), and geranial (9.1%), the amount of limonene is much lower at 0.3%.
Disc diffusion vapor assay for screening the inhibitory effect of CPV
Disc diffusion vapor assay was carried out by the method described by Goñi et al. and Edwards-Jones et al.. Overnight cultures of the S. aureus (7 log CFU/mL) were streaked on sterile TSA (Difco Laboratories, Inc.) using a cotton swab dipped into the culture. The swab was used to streak the agar plate to produce a lawn of growth by streaking the plate in 3 different directions. Ten μL of 100% CPV was aseptically pipetted onto sterile 6-mm paper discs (Becton Dickson, Franklin Lakes, NJ) and subsequently the CPV impregnated paper discs were aseptically placed in the centre of the lid of the Petri dish. Control plates were prepared by adding 10 μL of sterile water to the filter discs. The Petri dishes were subsequently sealed using parafilm and incubated at 37°C in an inverted position. The diameters of zones of inhibitions were measured in mm after 24 h of incubation. The assays were carried out on three different occasions in duplicate.
In vitro dressing model study
Keratinocyte cell culture
Homo sapiens skin keratinocyte (HEK001) ATCC CRL-2404™ cells were grown in keratinocyte serum free media (K-SFM) with two additives, bovine pituitary extracts (BPE) and human recombinant epidermal growth factor (EGF) (Invitrogen, Carlsbad, CA). Cells were grown routinely in a 75 cm2 flask at 37°C in a 5% CO2-humidified incubator. Ninety percent confluent cultures were trypsinized, and new cultures were prepared by seeding with 105 cells/ml in 75 cm2 flasks. For cytotoxicity and infection assays, BD Falcon™ 24-well tissue culture plates (BD, Franklin Lakes, NJ) were seeded with 105 cells/ml/well and incubated at 37°C in a humidified 5% CO2 incubator for 18 to 20 h to obtain a semi-confluent monolayer. Prior to assays, the monolayers were washed and incubated with K-SFM medium without antibiotic.
The MIC of CPV for the 6 S. aureus strains used in this study was previously determined as 0.18% for the strains 13136 p-m+ and 13136 p-m+V20 and 0.2% for strains COL, Mu50, and N315. Based on our previous results, 0.1% and 0.2% of CPV was prepared using dimethyl sulfoxide (DMSO) as a dispersing agent and added to the HEK001 cell monolayers and incubated for 24 h. After incubation, the cell monolayer was observed under phase-contrast microscope (Olympus, Japan). One set of HEK001 cell monolayer without any treatment and another set with equal volume of DMSO used in the CPV treatment were used as controls. To compare a typical cytotoxicity one set of HEK001 cell monolayer was treated with a known skin irritant SDS (25 μg/mL).
S. aureus infection assay
Adherence and invasion assays were performed using a modified procedure derived from Harvey et al.. Briefly, one loopful of overnight grown bacterial cells were collected from TSA plates and suspended in K-SFM media with additives. Aliquots (100 μl) of the bacterial suspension, containing approximately 7 log CFU/mL [multiplicity of infection (MOI) 1:100], were inoculated in duplicate in a 24-well tissue culture plate containing semi-confluent HEK001 cell monolayers. The CFUs of bacteria were determined simultaneously by serial dilution plate count on TSA plates. Infected monolayers were incubated for 2 h at 37°C under a 5% CO2 humidified atmosphere to allow the bacterial cells to adhere and infect the HEK001 cells. Infected HEK001 monolayers were washed five times with K-SFM medium and re-incubated for 3 h in fresh media containing 0.1 or 0.2% CPV. For controls, infected HEK001 monolayers were re-incubated with fresh K-SFM medium alone or K-SFM medium with equal volume of DMSO used in CPV treatment. After 1, 2, and 3 h of incubation both controls and CPV treated HEK001 cells were lysed with 0.1% Triton X (Sigma, St. Louis, MO) in PBS for 15 min to detach the bacterial cells and subsequently the lysate containing bacterial cells were diluted and viable intra- and extra-cellular bacterial numbers were determined by counting the CFU on TSA plate. Results are expressed as the average number of bacterial CFU from three assays.
Results and discussion
Effect of CPV vapour on S. aureus
In an effort to explore the potential use of orange EO against antibiotic resistant S. aureus, in our earlier study inhibitory effects and mode of action of CPV against methicillin-susceptible strain SH1000, MRSA strains COL, 13136 p-m+, and N315, and VISA strains 13136 p-m+ V20 , and Mu50 were studied. Compared to other tested EOs CPV effectively inhibited all the tested S. aureus strains. Therefore, in the present study the effect of CPV vapour on S. aureus was examined on both agar plates and an in vitro dressing model to evaluate the potential of CPV for topical therapy. Generally to study the antimicrobial effect of vapour, EO impregnated paper disc is placed on the lid of Petri dish and subsequently the growth inhibition zone is measured and used to indicate the antimicrobial effect of EO[19, 21].
Inhibitory effect of terpeneless cold pressed Valencia orange oil (CPV) against S. aureus strains determined by a disc-diffusion vapor assay
S. aureus strain
Inhibition Zone (mm)a
17.8 ± 1.4
64.0 ± 2.2
70.2 ± 1.4
78.8 ± 1.8
62.6 ± 2.5
21.0 ± 2.6
Antistaphylococcal effect of CPV vapor in dressing model
Our disc diffusion vapor assay proved that the vapor phase of the volatile components in the CPV serves as possible source of antimicrobial agents. Therefore, we considered assessment of the anti-staphylococcal effect of CPV vapor in an in vitro dressing model to evaluate the potential topical application of CPV. In this experiment the inhibitory effect of CPV was qualitatively evaluated by the presence or absence of inhibition zone by comparing the test and control dressing models (Figure1c-h). As we observed in the disc diffusion vapor assay a similar inhibitory effect was observed in the dressing model as well. Growth of MRSA strains COL and Mu50 and VISA strain 13136 p-m+ V20 was inhibited by the vapor released from the CPV spotted gauze dressing pad and exhibited a clear inhibition zones on agar plates (Figure1f-h). Our present study has demonstrated the potential of the CPV as an anti-MRSA agent in the vapor phase in both the disc diffusion assay and the in vitro dressing model. Effectiveness of the vapor phase EOs against microbial growth was shown to be better than the direct contact of EOs with the inoculated culture has already been reported in other studies[44, 50]. In an in vitro dressing model study Edwards-Jones et al. demonstrated the inhibitory effect of combination of geranium and commercial grapefruit extract Citricidal™ vapor against MRSA. Results of their study concluded that EOs can be applied as a natural anti-MRSA agent on the outer layer of the dressing without disturbing the normal wound healing process.
Non-cytotoxic effect of CPV on HEK001 keratinocyte cells
Anti-staphylococcal effect of CPV in S. aureus infected keratinocyte cells
Effect of CPV treatment on the total number of S. aureus infected with skin keratinocyte (HEK001) cell monolayer
S. aureus Strain
Initial Inoculuma(Log CFU/mL)
7.48 ± 0.16
5.53 ± 0.45
2.84 ± 0.20
2.18 ± 0.42
5.79 ± 0.07
2.06 ± 0.38
1.60 ± 0.00
6.30 ± 0.07
1.98 ± 0.45
13136 p-m+ V20
7.34 ± 0.11
5.04 ± 0.13
3.47 ± 0.20
2.62 ± 0.05
5.58 ± 0.06
2.83 ± 0.15
1.68 ± 0.15
5.88 ± 0.07
2.29 ± 0.62
MRSA is common in the U.S. and it accounts for more than half of all soft-tissue and skin infections. Surveillance reports indicate that in the U.S. annual MRSA prevalence continuously increased over the 10-year period from 32.7% in 1998 to 53.8% in 2007 and during the 1999–2006 the percentage of S. aureus infections resistant to methicillin increased greater than 90% in outpatients admitted to U.S. hospitals. Also, MRSA-related hospitalization rate per 1,000 discharges doubled in 2007[62, 63]. Despite major advances in wound and burn management in the new millennium, infection still remains an important factor in wound healing. Novel classes are clearly needed for MRSA, because current drug classes exhibit emerging resistance. We have initiated this study as a first step towards the investigation of potential antistaphylococcal effect of CPV and its usage for skin infection. In this study, we have demonstrated the antistaphylococcal effect of CPV in an in vitro dressing model and S. aureus infected keratinocyte cell culture study. Overall in the present study our findings suggest that further in vivo studies of CPV are warranted since the CPV showed the inhibition and bactericidal effect on MRSA and VISA in the in vitro models. While, we provide interesting and valuable basic data for CPV we suggest prior to continuing on for further studies to test the clinical safety and efficacy of the CPV to use as topical anti-MRSA agent comparison of the inhibitory effect of CPV with antibiotics currently used to treat MRSA skin infection would provide additional valid information for the future therapeutic applications.
In our earlier study we have reported the bacteriolytic effect and mechanism of action of CPV in antibiotic resistant S. aureus. The next step in this CPV series study focuses the comparison of the inhibitory effect of CPV with standard antibiotic disc assay together with a quality control strains to develop a standard evaluation method to test the inhibitory effect of CPV on more S. aureus strains and other pathogens.
Terpeneless cold-pressed valencia orange oil
Methicillin-resistant Staphylococcus aureus
Vancomycin intermediate-resistant Staphylococcus aureus.
- Otto M: Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol. 2010, 64 (1): 143-162. 10.1146/annurev.micro.112408.134309.View ArticlePubMed
- Chen AE, Goldstein M, Carroll K, Song X, Perl TM, Siberry GK: Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care. 2006, 22 (10): 717-10.1097/01.pec.0000236832.23947.a0.View ArticlePubMed
- Hersh AL, Chambers HF, Maselli JH, Gonzales R: National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008, 168 (14): 1585-1591. 10.1001/archinte.168.14.1585.View ArticlePubMed
- Kish TD, Chang MH, Fung HB: Treatment of skin and soft tissue infections in the elderly: A review. Am J Geri Pharmacother. 2010, 8 (6): 485-513. 10.1016/S1543-5946(10)80002-9.View Article
- Koerner R, Johnson AP: Changes in the classification and management of skin and soft tissue infections. J Antimicrob Chemother. 2011, 66 (2): 232-234. 10.1093/jac/dkq443.View ArticlePubMed
- Edwards-Jones V, Greenwood JE: What’s new in burn microbiology?: James Laing Memorial Prize Essay 2000. Burns. 2003, 29 (1): 15-24. 10.1016/S0305-4179(02)00203-6.View ArticlePubMed
- Guggenheim M, Zbinden R, Handschin AE, Gohritz A, Altintas MA, Giovanoli P: Changes in bacterial isolates from burn wounds and their antibiograms: A 20-year study (1986–2005). Burns. 2009, 35 (4): 553-560. 10.1016/j.burns.2008.09.004.View ArticlePubMed
- Edwards-Jones V, Dawson MM, Childs C: A survey into toxic shock syndrome (TSS) in UK burns units. Burns. 2000, 26 (4): 323-333. 10.1016/S0305-4179(99)00142-4.View ArticlePubMed
- Novick RP: MEDICINE: Combating Impervious Bugs. Science. 2008, 319 (5865): 910-911. 10.1126/science.1154769.View ArticlePubMed
- Pirri G, Giuliani A, Nicoletto SF, Pizzuto L, Rinaldi AC: Lipopeptides as anti-infectives: a practical perspective. Centr Eur J Biol. 2009, 4 (3): 258-273. 10.2478/s11535-009-0031-3.
- Stein RA: Antibiotic resistance: A global, interdisciplinary concern. The Am Biol Teacher. 2011, 73 (6): 314-321. 10.1525/abt.2011.73.6.3.View Article
- Saxena S, Kumar D: Tailoring biodiversity for the development of new therapeutics. Nat Prod Rad. 2002, 1: 18-25.
- Singh SB, Barrett JF: Empirical antibacterial drug discovery—Foundation in natural products. Biochem Pharmacol. 2006, 71 (7): 1006-1015. 10.1016/j.bcp.2005.12.016.View ArticlePubMed
- Butler MS, Buss AD: Natural products — The future scaffolds for novel antibiotics?. Biochem Pharmacol. 2006, 71 (7): 919-929. 10.1016/j.bcp.2005.10.012.View ArticlePubMed
- Patwardhan B, Mashelkar RA: Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward?. Drug Discov Today. 2009, 14 (15–16): 804-811.View ArticlePubMed
- Saleem M, Nazir M, Ali MS, Hussain H, Lee YS, Riaz N, Jabbar A: Antimicrobial natural products: an update on future antibiotic drug candidates. Nat Prod Rep. 2010, 27 (2): 238-254. 10.1039/b916096e.View ArticlePubMed
- McChesney JD, Venkataraman SK, Henri JT: Plant natural products: Back to the future or into extinction?. Phytochemistry. 2007, 68 (14): 2015-2022. 10.1016/j.phytochem.2007.04.032.View ArticlePubMed
- Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E: Methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982, 96 (1): 11-16.View ArticlePubMed
- Burt S: Essential oils: their antibacterial properties and potential applications in foods: a review. Inter J Food Microbiol. 2004, 94: 223-253. 10.1016/j.ijfoodmicro.2004.03.022.View Article
- Halcón L, Milkus K: Staphylococcus aureus and wounds: A review of tea tree oil as a promising antimicrobial. Am J Infect Con. 2004, 32 (7): 402-408. 10.1016/j.ajic.2003.12.008.View Article
- Fisher K, Phillips C: Potential antimicrobial uses of essential oils in food: is citrus the answer?. Trends Food Sci Technol. 2008, 19 (3): 156-164. 10.1016/j.tifs.2007.11.006.View Article
- Hammer KA, Carson CF, Riley TV, Nielsen JB: A review of the toxicity of Melaleuca alternifolia (tea tree) oil. Food Chem Toxicol. 2006, 44 (5): 616-625. 10.1016/j.fct.2005.09.001.View ArticlePubMed
- Cox S, Gustafson J, Mann C, Markham J, Liew Y, Hartland R, Bell H, Warmington J, Wyllie S: Tea tree oil causes K+ leakage and inhibits respiration in Escherichia coli. Lett Appl Microbiol. 1998, 26: 355-358. 10.1046/j.1472-765X.1998.00348.x.View ArticlePubMed
- Elsom GKF, Hide D: Susceptibility of methicillin-resistant Staphylococcus aureus to tea tree oil and mupirocin. J Antimicrob Chemother. 1999, 43 (3): 427-428. 10.1093/jac/43.3.427.View ArticlePubMed
- Hammer KA, Carson CF, Riley TV: Antimicrobial activity of essential oils and other plant extracts. J Appl Microbiol. 1999, 86 (6): 985-990. 10.1046/j.1365-2672.1999.00780.x.View ArticlePubMed
- May J, Chan CH, King A, Williams L, French GL: Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother. 2000, 45 (5): 639-643. 10.1093/jac/45.5.639.View ArticlePubMed
- Takarada K, Kimizuka R, Takahashi N, Honma K, Okuda K, Kato T: A comparison of the antibacterial efficacies of essential oils against oral pathogens. Oral Microbiol Immunol. 2002, 19: 61-4.View Article
- Brady A, Loughlin R, Gilpin D, Kearney P, Tunney M: In vitro activity of tea-tree oil against clinical skin isolates of meticillin-resistant and -sensitive Staphylococcus aureus and coagulase-negative staphylococci growing planktonically and as biofilms. J Med Microbiol. 2006, 55 (10): 1375-1380. 10.1099/jmm.0.46558-0.View ArticlePubMed
- Prabuseenivasan S, Jayakumar M, Ignacimuthu S: In vitro antibacterial activity of some plant essential oils. BMC Complem Alt Med. 2006, 6 (1): 39-10.1186/1472-6882-6-39.View Article
- Chao S, Young G, Oberg C, Nakaoka K: Inhibition of methicillin-resistant Staphylococcus aureus (MRSA) by essential oils. Flavour Fragrance J. 2008, 23 (6): 444-449. 10.1002/ffj.1904.View Article
- Fisher K, Phillips CA: The effect of lemon, orange and bergamot essential oils and their components on the survival of Campylobacter jejuni, Escherichia coli O157, Listeria monocytogenes, Bacillus cereus and Staphylococcus aureus in vitro and in food systems. J Appl Microbiol. 2006, 101 (6): 1232-1240. 10.1111/j.1365-2672.2006.03035.x.View ArticlePubMed
- O'Bryan CA, Crandall PG, Chalova VI, Ricke SC: Orange essential oils antimicrobial activities against Salmonella spp. J Food Sci. 2008, 73 (6): M264-M267. 10.1111/j.1750-3841.2008.00790.x.View ArticlePubMed
- Friedly EC, Crandall PG, Ricke SC, Roman M, O'Bryan C, Chalova VI: In vitro antilisterial effects of citrus oil fractions in combination with organic acids. J Food Sci. 2009, 74 (2): M67-M72. 10.1111/j.1750-3841.2009.01056.x.View ArticlePubMed
- Shannon EM, Milillo SR, Johnson MG, Ricke SC: Efficacy of cold-pressed terpeneless Valencia oil and its primary components on inhibition of Listeria species by direct contact and exposure to vapors. J Food Sci. 2011, 76 (7): M500-M503. 10.1111/j.1750-3841.2011.02337.x.View ArticlePubMed
- Nannapaneni R, Muthaiyan A, Crandall PG, Johnson MG, O'Bryan CA, Chalova VI, Callaway TR, Carroll JA, Arthington JD, Nisbet DJ: Antimicrobial activity of commercial citrus-based natural extracts against Escherichia coli O157: H7 isolates and mutant strains. Foodborne Pathog Dis. 2008, 5 (5): 695-699. 10.1089/fpd.2008.0124.View ArticlePubMed
- Nannapaneni R, Chalova VI, Crandall PG, Ricke SC, Johnson MG, O'Bryan CA: Campylobacter and Arcobacter species sensitivity to commercial orange oil fractions. Int J Food Microbiol. 2009, 129 (1): 43-49. 10.1016/j.ijfoodmicro.2008.11.008.View ArticlePubMed
- Muthaiyan A, Martin EM, Natesan S, Crandall PG, Wilkinson BJ, Ricke SC: Antimicrobial effect and mode of action of terpeneless cold-pressed Valencia orange essential oil on methicillin-resistant Staphylococcus aureus. J Appl Microbiol. 2012, 112 (5): 1020-33. 10.1111/j.1365-2672.2012.05270.x.PubMed CentralView ArticlePubMed
- Horsburgh MJ, Aish JL, White IJ, Shaw L, Lithgow JK, Foster SJ: sigmaB modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from Staphylococcus aureus 8325–4. J Bacteriol. 2002, 184 (19): 5457-67. 10.1128/JB.184.19.5457-5467.2002.PubMed CentralView ArticlePubMed
- Sabath LD, Wallace SJ, Byers K, Toftegaard I: Resistance of Staphylococcus aureus to penicillins and cephalosporins: reversal of intrinsic resistance with some chelating agents. Ann N Y Acad Sci. 1974, 236: 435-43. 10.1111/j.1749-6632.1974.tb41508.x.View ArticlePubMed
- Brown DF, Reynolds PE: Intrinsic resistance to beta-lactam antibiotics in Staphylococcus aureus. FEBS Lett. 1980, 122 (2): 275-278. 10.1016/0014-5793(80)80455-8.View ArticlePubMed
- Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y: Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 2001, 357 (9264): 1225-1240. 10.1016/S0140-6736(00)04403-2.View ArticlePubMed
- Pfeltz RF, Singh VK, Schmidt JL, Batten MA, Baranyk CS, Nadakavukaren MJ, Jayaswal RK, Wilkinson BJ: Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother. 2000, 44 (2): 294-303. 10.1128/AAC.44.2.294-303.2000.PubMed CentralView ArticlePubMed
- Braddock RJ: Handbook of citrus by-products and processing technology. 1999, Willey, New York
- Goñi P, López P, Sánchez C, Gómez-Lus R, Becerril R, Nerín C: Antimicrobial activity in the vapour phase of a combination of cinnamon and clove essential oils. Food Chem. 2009, 116 (4): 982-989. 10.1016/j.foodchem.2009.03.058.View Article
- Edwards-Jones V, Buck R, Shawcross SG, Dawson MM, Dunn K: The effect of essential oils on methicillin-resistant Staphylococcus aureus using a dressing model. Burns. 2004, 30 (8): 772-777. 10.1016/j.burns.2004.06.006.View ArticlePubMed
- Chung NM, Marshall CM, Leyden JJ, Lavker RM, Jensen PJ, Marsh BCR: Sodium dodecyl sulfate induces plasminogen activator inhibitor type 2 expression in epidermal keratinocytes in vivo and in vitro. J Invest Dermatol. 2001, 117 (3): 647-653. 10.1046/j.0022-202x.2001.01428.x.View ArticlePubMed
- Harvey HA, Jennings MP, Campbell CA, Williams R, Apicella MA: Receptor-mediated endocytosis of Neisseria gonorrhoeae into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor. Mol Microbiol. 2001, 42 (3): 659-672.View ArticlePubMed
- Dorman HJD, Deans SG: Antimicrobial agents from plants: antibacterial activity of plant volatile oils. J Appl Microbiol. 2000, 88 (2): 308-316. 10.1046/j.1365-2672.2000.00969.x.View ArticlePubMed
- Gaunt LF, Higgins SC, Hughes JF: Interaction of air ions and bactericidal vapours to control micro-organisms. J Appl Microbiol. 2005, 99 (6): 1324-1329. 10.1111/j.1365-2672.2005.02729.x.View ArticlePubMed
- Lopez P, Sanchez C, Batlle R, Nerin C: Solid-and vapor-phase antimicrobial activities of six essential oils: susceptibility of selected foodborne bacterial and fungal strains. J Agric Food Chem. 2005, 53 (17): 6939-6946. 10.1021/jf050709v.View ArticlePubMed
- Van de Sandt J, Roguet R, Cohen C, Esdaile D, Ponec M, Corsini E, Barker C, Fusenig N, Liebsch M, Benford D: The use of human keratinocytes and human skin models for predicting skin irritation. The Report and Recommendations of ECVAM Workshop. ATLA. 1999, 27: 723-744.PubMed
- Gallo RL, Nakatsuji T: Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol. 2011, 131 (October 2011): 1974-1980.PubMed CentralView ArticlePubMed
- Welss T, Basketter DA, Schröder KR: In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol In Vitro. 2004, 18 (3): 231-243. 10.1016/j.tiv.2003.09.009.View ArticlePubMed
- Woolf AD: Herbal remedies and children: Do they work? Are they harmful?. Pediatrics. 2003, 112 (1): 240-246.PubMed
- Dryden MS, Dailly S, Crouch M: A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect. 2004, 56 (4): 283-286. 10.1016/j.jhin.2004.01.008.View ArticlePubMed
- Sherry E, Warnke PH: Successful use of an inhalational phytochemical to treat pulmonary tuberculosis: A case report. Phytomedicine. 2004, 11 (2–3): 95-97.View ArticlePubMed
- Caelli M, Porteous J, Carson CF, Heller R, Riley TV: Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2000, 46 (3): 236-237.View ArticlePubMed
- Sherry E, Boeck H, Warnke P: Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic. BMC Surgery. 2001, 1 (1): 1-10.1186/1471-2482-1-1.PubMed CentralView ArticlePubMed
- Caelli M, Porteous J, Carson CF, Heller R, Riley TV: Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. Int J Aromather. 2001, 11 (2): 97-99. 10.1016/S0962-4562(01)80024-2.View Article
- Sherry E, Boeck H, Warnke PH: Topical application of a new formulation of eucalyptus oil phytochemical clears methicillin-resistant Staphylococcus aureus infection. Am J Infect Control. 2001, 29 (5): 346-346. 10.1067/mic.2001.117403.View ArticlePubMed
- Palaniappan K, Holley RA: Use of natural antimicrobials to increase antibiotic susceptibility of drug resistant bacteria. Int J Food Microbiol. 2010, 140 (2–3): 164-168.View ArticlePubMed
- Klein E, Smith DL, Laxminarayan R: Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999–2006. Emerg Infect Dis. 2009, 15 (12): 1925-1930. 10.3201/eid1512.081341.PubMed CentralView ArticlePubMed
- Mera RM, Suaya JA, Amrine-Madsen H, Hogea CS, Miller LA, Lu EP, Sahm DF, O'Hara P, Acosta CJ: Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: A 10-year trend of replacement and expansion. Microb Drug Resist. 2011, 17 (2): 321-328. 10.1089/mdr.2010.0193.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/125/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.